Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.
Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A. Miceli R, et al. Acta Oncol. 2024 Apr 21;63:213-219. doi: 10.2340/1651-226X.2024.24179. Acta Oncol. 2024. PMID: 38647024 Free article.
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment.
Giannatempo P, Paolini B, Miceli R, Raggi D, Nicolai N, Farè E, Catanzaro M, Biasoni D, Torelli T, Stagni S, Piva L, Mariani L, Salvioni R, Colecchia M, Gianni AM, Necchi A. Giannatempo P, et al. Among authors: miceli r. J Urol. 2013 Nov;190(5):1919-24. doi: 10.1016/j.juro.2013.04.057. Epub 2013 Apr 25. J Urol. 2013. PMID: 23624209
Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.
Pietrantonio F, Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, Iacovelli R, Miceli R, Bossi I, Leone G, Milione M, Pelosi G, de Braud F. Pietrantonio F, et al. Among authors: miceli r. PLoS One. 2014 Apr 1;9(4):e92147. doi: 10.1371/journal.pone.0092147. eCollection 2014. PLoS One. 2014. PMID: 24691006 Free PMC article.
Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.
Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, de Braud F, Floriani I, Miceli R. Di Bartolomeo M, et al. Among authors: miceli r. Gastric Cancer. 2016 Apr;19(2):412-420. doi: 10.1007/s10120-015-0495-y. Epub 2015 Apr 11. Gastric Cancer. 2016. PMID: 25862567 Clinical Trial.
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
Pietrantonio F, Mazzaferro V, Miceli R, Cotsoglou C, Melotti F, Fanetti G, Perrone F, Biondani P, Muscarà C, Di Bartolomeo M, Coppa J, Maggi C, Milione M, Tamborini E, de Braud F. Pietrantonio F, et al. Among authors: miceli r. Med Oncol. 2015 Jul;32(7):182. doi: 10.1007/s12032-015-0638-3. Epub 2015 May 24. Med Oncol. 2015. PMID: 26003673
Interim (18)F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions.
Necchi A, Nicolai N, Alessi A, Miceli R, Giannatempo P, Raggi D, Tana S, Serafini G, Padovano B, Mariani L, Crippa F, Salvioni R. Necchi A, et al. Among authors: miceli r. Clin Genitourin Cancer. 2016 Jun;14(3):249-54. doi: 10.1016/j.clgc.2015.08.010. Epub 2015 Sep 5. Clin Genitourin Cancer. 2016. PMID: 26433626
429 results